Overview of Research into mTOR Inhibitors [PDF]
Molecules, 2022 The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family.
Beibei Mao +5 more
doaj +2 more sources
The Role of mTOR Inhibitors in COVID-19 Outcomes Among Heart Transplant Recipients [PDF]
VirusesBackground: Heart failure (HF) remains a major global health challenge, with orthotopic heart transplantation (OHT) serving as the gold-standard therapy for end-stage disease.
Agnieszka Kuczaj +8 more
doaj +2 more sources
Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age [PDF]
Neurology and Therapy, 2023 Introduction Mechanistic target of rapamycin (mTOR) inhibitors sirolimus and everolimus are an effective therapy for subependymal giant cell astrocytomas, cardiac rhabdomyomas, renal angiomyolipomas, and lymphangioleiomyomatosis associated with tuberous ...
Dominika Śmiałek +3 more
doaj +2 more sources
Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension [PDF]
JACC: Basic to Translational Science, 2018 Summary: Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial ...
Haiyang Tang, PhD +18 more
doaj +4 more sources
In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease [PDF]
SLAS Technology, 2023 Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and is characterized by the formation of renal cysts and the eventual development of end-stage kidney disease.
Alysia Cox +4 more
doaj +2 more sources
Perfect match: mTOR inhibitors and tuberous sclerosis complex [PDF]
Orphanet Journal of Rare Diseases, 2022 Highlights Hyperactivation of mammalian target of rapamycin (mTOR) is essential in the pathogenesis of tuberous sclerosis complex (TSC) and can serve as a therapeutic target. mTOR inhibitors have shown considerable success in multiple clinical trials for
Cong Luo +8 more
doaj +2 more sources
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]
, 2013 Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Badura, Susanne +8 more
core +10 more sources
Cancer and mTOR inhibitors in kidney transplantation recipients [PDF]
PeerJ, 2018 Background Previous studies show that mTOR inhibitors decrease the risk of cancer development after kidney transplantation. However, the effect of cumulative doses of mTOR inhibitors on cancer after kidney transplantation is not well known.
Chih-Chin Kao +8 more
doaj +2 more sources
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
Frontiers in Pharmacology, 2022 The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway.
Xianbo Wu +7 more
doaj +1 more source
Current Research in Pharmacology and Drug Discovery, 2022 The mammalian target of rapamycin (mTOR) plays an important role in the aggressiveness and therapeutic resistance of many cancers. Targeting mTOR continues to be under clinical investigation for cancer therapy.
David Danielpour +3 more
doaj +1 more source